5-甲基-2-氨基-3-硝基吡啶 | 7598-26-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 5-甲基-2-氨基-3-硝基吡啶
• 中文别名: 2-氨基-3-硝基-5-甲基吡啶；6-氨基-5-硝基-3-甲基吡啶；2-氨基-5-甲基-3-硝基吡啶
• 英文名称: 5-methyl-3-nitropyridin-2-amine
• 英文别名: 2-amino-5-methyl-3-nitropyridine；5-Methyl-3-nitro-2-aminopyridine
• CAS: 7598-26-7
• 化学式: C₆H₇N₃O₂
• mdl: MFCD00047442
• 分子量: 153.14
• InChiKey: ZJKGRSJMFDIRPX-UHFFFAOYSA-N

物化性质

• 熔点：
  189-193 °C
• 沸点：
  318.9±37.0 °C(Predicted)
• 密度：
  1.354±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料、热源或火焰接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  密封存储，应存放在阴凉干燥的仓库中。

SDS

Name:	6-Amino-5-nitro-3-picoline Material Safety Data Sheet
Synonym:	2-Amino-5-methyl-3-nitropyridine
CAS:	7598-26-7

Section 1 - Chemical Product MSDS Name:6-Amino-5-nitro-3-picoline Material Safety Data Sheet
Synonym:2-Amino-5-methyl-3-nitropyridine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7598-26-7	6-Amino-5-nitro-3-picoline	100	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7598-26-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7N3O2
Molecular Weight: 153.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, exposure to flame.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, acid anhydrides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7598-26-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Amino-5-nitro-3-picoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 7598-26-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7598-26-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7598-26-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-2-氨基-3-硝基吡啶 在 氢溴酸 、 溴 、 sodium nitrite 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 2.0h， 以28%的产率得到2-溴-3-硝基-5-甲基吡啶
  参考文献：
  名称：

  WO2006/76644

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 在 硫酸 、 硝酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.5h， 以27%的产率得到5-甲基-2-氨基-3-硝基吡啶
  参考文献：
  名称：

  WO2006/76644

  摘要：

  公开号：

文献信息

• [EN] 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES<br/>[FR] 4-MÉTHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTALÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019979A1

  公开（公告）日：2014-02-06

  The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  该发明涉及一般式(I)的4-甲基-2,3,5,9,9b-五氮杂-环戊[α]萘衍生物，它们是磷酸二酯酶2和/或10的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
  申请人：GIOVANNINI Riccardo

  公开号：US20140045856A1

  公开（公告）日：2014-02-13

  The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  这项发明涉及一般式(I)的4-甲基-2,3,5,9,9b-五氮杂-环戊[α]萘衍生物，它们是磷酸二酯酶2和/或10的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• 苯并咪唑类衍生物、其制备方法及其在医药学上的应用
  申请人：北京诺诚健华医药科技有限公司

  公开号：CN109956927A

  公开（公告）日：2019-07-02

  本发明涉及一种新的调控或抑制吲哚胺2,3‑双加氧酶（IDO）活性的苯并咪唑类衍生物，其制备方法及其在医药学上的应用。具体而言，本发明涉及一种通式（I）所示的化合物及其可药用的盐、含有所述化合物或其可药用的盐的药物组合物、应用所述化合物或其可药用的盐治疗和/或预防IDO介导的相关性病症、特别是肿瘤的方法以及所述化合物或其可药用的盐的制备方法。本发明还涉及所述化合物或其可药用的盐或含有所述化合物或其可药用的盐的药物组合物在制备用于治疗和/或预防IDO介导的相关性病症、特别是肿瘤的药物中的用途。其中通式（I）的各取代基与说明书中的定义相同。
• NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES
  申请人：Ho Pil Su

  公开号：US20140315888A1

  公开（公告）日：2014-10-23

  The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.

  该发明涉及新型杂环化合物，用于制备治疗与组织胺4受体的各种功能相关的疾病的药物。特别是，所述药物适用于治疗炎症性疾病、过敏、疼痛、鼻息肉、鼻炎、慢性鼻窦炎、鼻塞、鼻痒、哮喘、慢性阻塞性肺病、类风湿性关节炎、特应性皮炎、牛皮癣、湿疹、瘙痒、瘙痒皮肤、荨麻疹、特发性慢性荨麻疹、硬皮病、结膜炎、角膜结膜炎、眼部炎症、干眼症、心脏功能障碍、心律失常、动脉粥样硬化、多发性硬化、炎症性肠病（包括结肠炎、克罗恩病、溃疡性结肠炎）、炎症性疼痛、神经痛、骨关节炎疼痛、自身免疫性甲状腺疾病、免疫介导（也称为I型）糖尿病、红斑狼疮、术后粘连、前庭障碍和癌症的药物治疗。
• [EN] AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS D'AMINOQUINOLÉINE COMME AGENTS ANTIVIRAUX
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012037108A1

  公开（公告）日：2012-03-22

  Provided are compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是式(I)和式(II)的化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒介导的病毒感染，如丙型肝炎病毒（HCV）。